Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

Cancer

Volumn 62, Issue 3, 1988, Pages 479-483

  Lai, Ching‐Lung ^a   Lok, Anna Suk‐Fong ^a   Wu, Pui‐Chee ^a   Chan, Gerald Chee‐Bunn ^b   Lin, Hsiang‐Ju ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

AGE; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPTICEMIA;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; COMPARATIVE STUDY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RANDOM ALLOCATION;

EID: 0023765990     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L     Document Type: Article

References (19)

1. Treatment of heptocellular carcinoma with adriamycin
2. Doxorubicin for liver cancer
3. A phase II study of adriamycin (NSC 123127) in patients with hepato‐cellular carcinoma from Zambia and the United States
4. Chemotherapy studies in primary liver cancer
5. Induction of remission in hepatocellular carcinoma with doxorubicin
6. Further experience in treating patients with hepatocellular carcinoma in Uganda
7. Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma
8. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma
9. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy
10. Adriamycin cardiotoxicity
11. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
12. Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong
13. Adriamycin treatment for hepatocellular carcinoma: Experience with 109 patients
14. Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicin
15. Distribution and antitumour activity of adriamycin given in a high dose and a repeated low dose schedule to mice
16. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
17. Epirubicin: A therapeutically active doxorubicin analogue with reduced cardiotoxicity
18. Chronic hepatitis B related diseases in Hong Kong